News + Press

Fuld + Company Welcomes Health & Life Sciences Practice Leader, Michael Ratcliffe

Posted November 26, 2019| Michael Ratcliffe , Fuld + Company

Michael Ratcliffe brings both deep industry expertise and intelligence and strategy consulting capabilities to the firm.

Michael Ratcliffe | Health + Life Science Lead, Fuld + Company

Boston, Mass. November 26, 2019— Fuld + Company, a global competitive strategy consultancy, today announced the recent appointment of Michael Ratcliffe as a Senior Director and Head of the Health & Life Sciences Practice. In this role, he will support efforts to advance the practice line, and deliver competitive intelligence, strategic insights, and consulting services to Fuld’s portfolio of pharmaceutical, payer, provider and healthcare technology company clients.

Drawing from his 30 years of experience in various strategy consulting and competitive intelligence roles across firms like McKinsey & Co, DRI-McGraw Hill, Stanford Research Institute Consulting and Wood Mackenzie, Ratcliffe, brings an impressive track-record to the firm. Through this cumulative experience applying qualitative and quantitative research techniques and analysis, Mike is a proven resource, helping clients tackle tough competitive strategy issues.

“Mike is a highly regarded strategy and intelligence professional in the health and life sciences industry and we are thrilled to have him join Fuld + Company.  His strengths in research and analysis coupled with his ability to lead make him the great fit for this role,” said Diane Borska, Fuld + Company CEO. “Mike has a broad and deep understanding of the U.S. healthcare market’s changing structure, and the macro forces driving change across global healthcare, pharmaceutical, diagnostics, biotechnology, and insurance markets. These insights will undoubtedly add immense value to our client engagements and internal teams.”

Prior to joining Fuld + Company, Ratcliffe launched and ran EMC Analytics where he managed engagements focused on the U.S. healthcare market, as well as the European, Latin American and Chinese markets. He was a recipient of the 2016 PharmaCI award for the “most innovative approach to CI,” for his work researching the Integrated Delivery Network (IDN) market in the U.S.

Of further note, Ratcliffe is the co-author of the book titled, “Best Practices in Managing Competitive Intelligence Research.” He is frequently invited to deliver seminars at various universities and is slated to publish a new book in 2020 on competitive intelligence topics.

A native of the United Kingdom, Ratcliffe earned a bachelor’s degree and a master’s degree in Physics from Oxford University and studied economics at the London School of Economics. He currently resides in Easton, Mass with his wife.

 

About Fuld + Company

Fuld + Company is a competitive strategy consultancy that helps clients anticipate competitive activity, see beyond market disruptions and develop or refine robust business strategies. Through research and evidence-based analysis, Fuld + Company delivers sound expertise to solve complex and tactical challenges for its Global Fortune 1000 clients.  Fuld + Company is celebrating its 40th year in business and is a pioneer in competitive strategy consulting.  Its leaders have been recognized by top-tiered publications such as: Fortune, The Harvard Business Review & Fast Company. 

 

Tags: , , ,

Related Resources

Read More

Fuld + Company Announces New, Senior Hire for Energy Practice

Keith McWhorter, MBA, Brings Strong Domain Knowledge, Strategy, Analysis and Research Capabilities to the Firm Boston, Mass. July 11, 2019—Fuld […]

Read More

Analysis Of The Trastuzumab Biosimilar Market As Herceptin Exclusivity Nears An End

To expand on the Fuld + Company, Pharma Companies to Watch Report, Analyst Robert Browne drilled in on the Biosimilar Marketplace in […]

Read More

Evolution In Prostate Cancer Diagnostics Creates New Opportunities For Medtech

In the US, prostate cancer remains a challenge for men’s health, with approximately 174,650 new cases expected in 2019, third […]

Subscribe to our mailing list for our latest updates: